Abstract
Insulin-like growth factors (IGFs) regulate breast cancer cell proliferation, protect cells from apoptosis, and enhance metastasis. In this study, we examined the IGF signaling pathway in two breast cancer cell lines selected for metastatic behavior. LCC6 was selected for growth as an ascites tumor in athymic mice from parental MDA-MB-435 cells (435P). The MDA-231BO cell line was derived from osseous metastases that formed after intracardiac injection of the MDA-MB-231 cell line in athymic mice. Compared to the parental cell lines, IGF-I treatment enhanced IRS-2 phosphorylation over IRS-1 in the metastatic variants. IGF-I stimulated cell migration in the variant cells, but not in the parental cells. To determine the role for IRS-2 in IGF-mediated motility, we transfected MDA-231BO cells with an anti-sense IRS-2 construct. Transfected cells had decreased levels of IRS-2 with diminished IGF-mediated motility and anchorage independent growth when compared to control cells. However, adherence to fibronectin was enhanced in the transfected cells compared to MDA-231BO cells. Our data show that breast cancer cells selected for metastatic behavior in vivo have increased IRS-2 activation and signaling. In these cells, IGF-I enhances cell adhesion and motility suggesting that IRS-2 may mediate these aspects of the malignant phenotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G, Marvaldi J, Luis J . 1999 Int. J. Cancer 83: 497–505
Clark SF, Molero JC, James DE . 2000 J. Biol. Chem 275: 3819–3826
Clemmons DR, Horvitz G, Engleman W, Nichols T, Moralez A, Nickols GA . 1999 Endocrinology 140: 4616–4621
Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N . 1990 Cancer Res. 50: 48–53
Doerr ME, Jones JI . 1996 J. Biol. Chem. 271: 2443–2447
Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett CJ . 1998 Cancer Res. 58: 3353–3361
Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH . 1999 J. Cell. Biol. 144: 1337–1348
Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D . 1993 J. Cell. Physiol. 157: 229–236
Gooch JL, Van Den Berg CL, Yee D . 1999 Breast Cancer Res. Treat. 56: 1–10
Gui GP, Puddefoot JR, Vinson GP, Wells CA, Carpenter R . 1997 Br. J. Cancer 75: 623–633
Guvakova MA, Surmacz E . 1997 Exp. Cell Res. 231: 149–162
Guvakova MA, Surmacz E . 1999 Exp. Cell Res. 251: 244–255
Jackson JG, White MF, Yee D . 1998 J. Biol. Chem. 273: 9994–10003
Jackson JG, Yee D . 1999 Growth Horm. IGF Res. 9: 280–289
Jackson JG, Yoneda T, Clark GM, Yee D . 2000 Clin. Cancer Res. 6: 1135–1139
Klemke RL, Yebra M, Bayna EM, Cheresh DA . 1994 J. Cell. Biol. 127: 859–866
Lauffenburger DA, Horwitz AF . 1996 Cell 84: 359–369
Lebrun P, Baron V, Hauck CR, Schlaepfer DD, Van Obberghen E . 2000 J. Biol. Chem. 275: 38371–38377
Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D . 2000 Mol. Cell. Biol. 20: 1489–1496
Lee YJ, Streuli CH . 1999 J. Biol. Chem. 274: 22401–22408
Leonessa F, Green D, Licht T, Wright A, Wingatelegette K, Lippman J, Gottesman MM, Clarke R . 1996 Br. J. Cancer 73: 154–161
Long L, Rubin R, Baserga R, Brodt P . 1995 Cancer Res. 55: 1006–1009
Long L, Rubin R, Brodt P . 1998 Exp. Cell Res. 238: 116–121
Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R . 2001 Oncogene 20: 490–500
Shaw LM . 2001 Mol. Cell. Biol. 21: 5082–5093
Smith LK, Vlahos CJ, Reddy KK, Falck JR, Garner CW . 1995 Mol. Cell. Endocrinol. 113: 73–81
Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffmann E . 1989 J. Biol. Chem. 264: 21544–21549
Tanti JF, Gremeaux T, van Obberghen E, Le Marchand-Brustel Y . 1994 J. Biol. Chem. 269: 6051–6057
Vuori K, Ruoslahti E . 1994 Science 266: 1576–1578
Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R . 2001 J. Bone Miner. Res. 16: 1486–1495
Yu GH, Cajulis RS, De Frias DV . 1998 Am. J. Clin. Pathol. 109: 315–319
Zutter MM, Sun H, Santoro SA . 1998 J. Mammary Gland Biol. Neoplasia 3: 191–200
Acknowledgements
This was supported by Public Health Service (PHS) grant R01CA74285, and PHS Cancer Center Support grant P30CA54174. Drs Robert Clark and Nils Brünner kindly provided the MDA-MB-435 parental and LCC6 variant cells. The authors wish to thank Adrian V Lee and Carol Lange for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jackson, J., Zhang, X., Yoneda, T. et al. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20, 7318–7325 (2001). https://doi.org/10.1038/sj.onc.1204920
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204920
Keywords
This article is cited by
-
Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer
Advances in Therapy (2023)
-
Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer
British Journal of Cancer (2021)
-
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer
BMC Cancer (2018)
-
Overexpression of insulin receptor substrate-4 is correlated with clinical staging in colorectal cancer patients
Journal of Molecular Histology (2018)
-
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells
Hormones and Cancer (2018)